Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mink Therapeutics Inc (INKT)

Mink Therapeutics Inc (INKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,783
  • Shares Outstanding, K 4,523
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,510 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 0.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.86
  • Number of Estimates 2
  • High Estimate -0.80
  • Low Estimate -0.91
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -72.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.68 +7.89%
on 11/04/25
15.35 -10.88%
on 10/21/25
-0.32 (-2.29%)
since 10/10/25
3-Month
12.68 +7.89%
on 11/04/25
18.17 -24.71%
on 08/15/25
-0.52 (-3.66%)
since 08/12/25
52-Week
4.56 +199.99%
on 01/28/25
76.00 -82.00%
on 07/11/25
+5.88 (+75.38%)
since 11/12/24

Most Recent Stories

More News
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1 Evidence of immune activation and tumor-immune...

INKT : 13.68 (+0.15%)
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...

INKT : 13.68 (+0.15%)
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...

INKT : 13.68 (+0.15%)
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced...

INKT : 13.68 (+0.15%)
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced...

INKT : 13.68 (+0.15%)
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD) Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE)...

INKT : 13.68 (+0.15%)
New Strong Sell Stocks for August 22nd

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:MiNK Therapeutics, Inc. INKT is a clinical stage biotechnology company pioneering the discovery, development, and commercialization...

MNR : 11.98 (+1.70%)
CSIQ : 28.46 (-4.50%)
INKT : 13.68 (+0.15%)
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer Department of Defense STTR Grant to advance INKTs in GVHD announced; program advancing New clinical grant...

INKT : 13.68 (+0.15%)
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...

INKT : 13.68 (+0.15%)
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today...

INKT : 13.68 (+0.15%)

Business Summary

MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York....

See More

Key Turning Points

3rd Resistance Point 14.79
2nd Resistance Point 14.49
1st Resistance Point 14.08
Last Price 13.68
1st Support Level 13.37
2nd Support Level 13.07
3rd Support Level 12.66

See More

52-Week High 76.00
Fibonacci 61.8% 48.71
Fibonacci 50% 40.28
Fibonacci 38.2% 31.85
Last Price 13.68
52-Week Low 4.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar